New drug combo aims to tame chronic hepatitis b
NCT ID NCT06706310
First seen Jan 04, 2026 · Last updated Jun 19, 2026 · Updated 30 times
Summary
This Phase 2 trial tests whether adding TQ-A3334 tablets to standard nucleoside analog therapy can better control chronic hepatitis B. 116 adults with the infection will receive either TQ-A3334 or a placebo, plus standard antivirals. The main goal is to see if the combination lowers HBsAg levels more than standard treatment alone after 24 weeks.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for CHRONIC HEPATITIS B are added.
Genom att skicka in godkänner du våra Användarvillkor
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
Genom att skicka in godkänner du våra Användarvillkor
Locations
-
First People's Hospital of Yunnan Province
Kunming, Yunnan, 650034, China
-
Hospital workers in Liuzhou
Liuzhou, Guangxi, 545000, China
-
Peking University Shenzhen Hospital
Shenzhen, Guangdong, 518036, China
-
People's Hospital Of RuiAn City
Rui’an, Zhejiang, 325200, China
-
Pu'er People's Hospital
Pu'er, Yunnan, 665099, China
-
The Fifth People's Hospital of Wuxi (Affiliated Wuxi Fifth Hospital of Jiangnan University)
Wuxi, Jiangsu, 214001, China
-
The First Affiliated Hospital of Chongqing Medical University
Chongqing, Chongqing Municipality, 400016, China
-
The First Affiliated Hospital of Xi'an Jiao Tong University
Xi'an, Shaanxi, 710000, China
-
The First Affiliated Hospital of Xinjiang Medical University
Ürümqi, Xinjiang, 831400, China
-
The Second XIANGYA Hospital Of Central South University
Changsha, Hunan, 410008, China
-
The Sixth People's Hospital of Shenyang
Shenyang, Liaoning, 110000, China
-
The Third Affiliated Hospital of Sun Yat-sen University
Guangzhou, Guangdong, 510000, China
-
The first hospital of Jilin University
Changchun, Jilin, 130021, China
-
West China Hospital of Sichuan University
Chengdu, Sichuan, 610044, China
-
WuHan Jinyintan Hospital
Wuhan, Hubei, 430023, China
What this could mean
Our plain-language read of the trial. This is informational only — not medical advice or a prediction.
Active substance
TQ-A3334 tablet combined with nucleoside analogs
What this could lead to
If successful, this combination could improve control of chronic hepatitis B by reducing HBsAg levels, potentially leading to better long-term disease management.
What could go wrong
This is an early Phase 2 trial with only 116 participants, so results may not be conclusive. The treatment may not significantly outperform placebo, and side effects are still being evaluated.
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.